- Home
- HIO vs OTLK Comparison
HIO vs OTLK Comparison
Compare HIO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIO | OTLK |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.9M | 249.6M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HIO | OTLK |
|---|---|---|
| Price | $3.25 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.03 |
| AVG Volume (30 Days) | 732.8K | ★ 3.7M |
| Earning Date | 01-01-0001 | 08-14-2026 |
| Dividend Yield | ★ 10.33% | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,355.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $0.16 |
| 52 Week High | $3.86 | $2.54 |
Technical Indicators
Market Signals| Indicator | HIO | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 44.49 |
| Support Level | $3.21 | $0.53 |
| Resistance Level | $3.33 | $0.60 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 43.33 | 63.44 |
Price Performance
Historical ComparisonAbout HIO Western Asset High Income Opportunity Fund Inc.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.